ARROWHEAD PHARMACEUTICALS ($ARWR) posted quarterly earnings results on Thursday, August 7th. The company reported earnings of -$1.26 per share, missing estimates of -$1.05 by $0.21. The company also reported revenue of $27,770,000, beating estimates of $24,185,332 by $3,584,668.
You can see Quiver Quantitative's $ARWR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARROWHEAD PHARMACEUTICALS Insider Trading Activity
ARROWHEAD PHARMACEUTICALS insiders have traded $ARWR stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
- CHRISTOPHER RICHARD ANZALONE (Chief Executive Officer) has made 0 purchases and 8 sales selling 492,547 shares for an estimated $7,582,644.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARROWHEAD PHARMACEUTICALS Hedge Fund Activity
We have seen 124 institutional investors add shares of ARROWHEAD PHARMACEUTICALS stock to their portfolio, and 140 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 3,748,154 shares (+23.2%) to their portfolio in Q1 2025, for an estimated $47,751,481
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 2,774,933 shares (+138.0%) to their portfolio in Q1 2025, for an estimated $35,352,646
- FMR LLC removed 1,786,001 shares (-35.0%) from their portfolio in Q1 2025, for an estimated $22,753,652
- JPMORGAN CHASE & CO removed 1,532,755 shares (-75.9%) from their portfolio in Q1 2025, for an estimated $19,527,298
- VANGUARD GROUP INC added 1,018,273 shares (+8.4%) to their portfolio in Q1 2025, for an estimated $12,972,798
- STATE STREET CORP added 983,022 shares (+16.3%) to their portfolio in Q1 2025, for an estimated $12,523,700
- CITADEL ADVISORS LLC added 618,953 shares (+168.2%) to their portfolio in Q1 2025, for an estimated $7,885,461
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARROWHEAD PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ARWR in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 05/20/2025
- Chardan Capital issued a "Buy" rating on 05/13/2025
- B. Riley Securities issued a "Buy" rating on 02/14/2025
- RBC Capital issued a "Outperform" rating on 02/11/2025
To track analyst ratings and price targets for ARROWHEAD PHARMACEUTICALS, check out Quiver Quantitative's $ARWR forecast page.
ARROWHEAD PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 5 analysts offer price targets for $ARWR in the last 6 months, with a median target of $42.0.
Here are some recent targets:
- Patrick Trucchio from HC Wainwright & Co. set a target price of $80.0 on 05/20/2025
- Shawn Egan from Citigroup set a target price of $17.0 on 05/13/2025
- Keay Nakae from Chardan Capital set a target price of $60.0 on 05/13/2025
- Mayank Mamtani from B. Riley Securities set a target price of $38.0 on 02/14/2025
- Luca Issi from RBC Capital set a target price of $42.0 on 02/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
